Studies have indicated that inhibiting lactate dehydrogenase A (LDHA) in conjunction with TKIs such as imatinib enhances the efficacy of treatment in chronic myeloid leukemia (CML), where lactate accumulation is known to promote drug resistance 98. Here, LDHA is linked to chronic myelogenous leukemia, BCR-ABL1 positive.